Based on high Met gene expression and constitutive MET phosphorylation in the tumor tissue (Fig. 1B, Additional file 1: Fig. S2), the SMA-560 model was selected to assess the effects of radiotherapy in combination with pharmacologic inhibition of MET by tepotinib in vivo. Here, MET is linked to neoplasm.